
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical is poised for a positive outlook driven by several key factors, including anticipated faster growth in the spine market and an increase in sales from its Enabling Technologies segment, which could lead to improved profit margins. The company's fourth-quarter performance, highlighted by a 10% growth largely due to strong U.S. spine sales, reinforces confidence in its revenue trends and signals potential upside to future guidance. Additionally, as Globus Medical capitalizes on integration opportunities and lowers manufacturing costs, it is expected to achieve significant EBITDA margin stabilization around 34-35% by 2026, which will contribute to strong free cash flow and enhance balance sheet flexibility.
Bears say
Globus Medical faces significant risks that contribute to a negative outlook, including slower-than-expected growth in the spine market and potential revenue disruption from recent mergers with NuVasive and Nevro. The bear case scenario suggests a bleak revenue growth forecast of low single digits, accompanied by flat margins and heightened downside risks from competitive dynamics and underperformance of key product launches. Additionally, the potential for declining operating margins and challenges in market expansion within the musculoskeletal space raise further concerns about the company's financial stability.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares